Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gujarat Terce Laboratories has published its unaudited financial results for the third quarter and nine months ended December 31, 2025, which were approved by the Board on February 4, 2026. For Q3 FY26, revenue from operations came in at Rs. 1,229.35 lakhs, down slightly from Rs. 1,268.08 lakhs in the year-ago quarter, while profit after tax fell to Rs. 76.11 lakhs from Rs. 100.80 lakhs, a drop of about 24%. For the nine months ended December 2025, revenue declined to Rs. 3,607.34 lakhs from Rs. 3,787.08 lakhs, and profit after tax slipped to Rs. 211.05 lakhs from Rs. 241.26 lakhs. Earnings per share for the nine-month period stood at Rs. 2.70 versus Rs. 3.25 in the prior year. Pre-tax profit actually improved year-on-year in both periods, suggesting margin expansion that was eroded by a higher tax outflow this year.
Shareholders should note a modest revenue decline combined with a meaningful drop in net profit and EPS for both the quarter and the nine-month period, even though operating profits strengthened. The weaker bottom-line print relative to a stronger pre-tax result points to higher tax incidence this year, which may keep the stock under pressure in the near term.